Multiple sclerosis (MS) is primarily a disease of young adults, particularly women. Evidence suggests that MS is, in part, a disease in which the immune system attacks protein components of myelin.
Meridian is conducting a Phase 3 clinical trial for an investigational medication intended to help control muscle spasms in people with MS.
- Must be age 18 or older and have been diagnosed with multiple sclerosis (any subtype) for at least 1 year
- Must have had treatment with at least 1 optimized oral antispasticity (including either oral baclofen or oral tizanidine)
- Must currently be receiving at least 1 antispasticity medication (baclofen, tizanidine, or dantrolene) but still suffering from spasms
- If receiving any other MS-modifying therapy, must be at a stable dose for at least 3 months
- Will receive compensation for study-related time
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can also talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.
Submit your information
Meridian Clinical Research
6602 Waters Avenue, Building C
Savannah, GA 31406
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.